Tigran Makunts
5PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|May 13, 2024
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis".Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
|May 13, 2024
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
|Feb 26, 2024
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events.Tigran Makunts, Siranuysh Grabska, Hovakim Grabski
|Dec 04, 2023
Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System.Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
|Feb 10, 2022
Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events.Tigran Makunts, Keith Burkhart, Ruben Abagyan
Pageof 1
